@Arkain2K this is about the German company Curevac. They developed an mRNA vaccine that they expect to be approved in 3-4 weeks from now. Interview is auto-translated from https://www.swp.de/suedwesten/staed...lassung-in-drei-bis-vier-wochen-56479145.html
via DeePL.
Curevac already has produced millions of doses that can instantly be deployed upon approval.
Now there's a name that made wave early on and quickly fell behind the pack, much like Novavax. I do know the E.U did put in a preorder of 225M doses with them (pending approval) at €10 (~$12) per shot last November, but in all likelihood they'll probably be playing second-fiddle.
I believe CureVac only have plan to hold their Phase 3 clinical trials in Europe and Latin America, of which the recruitment process barely completely this month, there's literally no trials data for anyone to review, so I find their incredibly optimistic expectation for EMA approval "3-4 weeks from now" to be highly unlikely, given the fact that Novavax published their successful U.K trials result nearly 3 months ago and still isn't approved yet.
Let's circle May 18-27 on the calendar and we'll see how close they are, but I'm predicting that they wouldn't be approved until at least Summer, and by then their overall contribution to the U.K/E.U's 2021 vaccination effort will likely be as minor as J&J in the U.S, especially now that the E.U has decided to bet the entire farm on Pfizer-BioNTech, this year AND the next.
As I understand it the EU are paying AZ something like £3 per jab and the UK are paying £14 per jab.
The EU signed their deal 1 day before the UK but AZ (understandably from a certain point of view) decided to ship the more profitable order first.
I think there is no way AZ will not feel the fallout from this. Optics are very important to politicians and quite a few continental leaders got burned by AZ decision.
I predict the fall out for AZ will be much longer than Covid.
The European Commission didn't do much by way of due diligence on the AZ contract and besides I'm not sure how suing is going to speed up supply which is the stated aim of this , and it does seems a little perverse to be suing over supply shortfall when some member states seem reluctant to use the AZ vaccines that are already available within the EU .
As I understand it the EU are paying AZ something like £3 per jab and the UK are paying £14 per jab.
The EU signed their deal 1 day before the UK but AZ (understandably from a certain point of view) decided to ship the more profitable order first.
I think there is no way AZ will not feel the fallout from this. Optics are very important to politicians and quite a few continental leaders got burned by AZ decision.
I predict the fall out for AZ will be much longer than Covid.
https://www.reuters.com/world/europe/spain-extend-gap-between-astrazeneca-doses-16-weeks-2021-04-30/Spain is extending the gap between the first and second doses of AstraZeneca's (AZN.L) COVID-19 vaccine to 16 weeks for people aged under 60, the government said on Friday, going beyond the 12-week maximum interval approved by European authorities.
Spain is the first country to diverge from the European Medicines Agency's (EMA) authorisation and promote "off label use", which would not be approved by the regulator and would leave individual nations responsible for any possible side-effects.
The extension gives authorities more breathing space to determine the safest way to administer the vaccine, the health ministry said. Spain initially gave AstraZeneca shots to essential workers aged 18-65 before allowing only people aged over 60 to received the vaccine due to concerns about blood clots in younger people.
The EMA's approval for the vaccine is based on the second dose being administered between four and 12 weeks after the first. A 16-week interval has not been tested in any human trials.
AstraZeneca and the EMA did not immediately respond to requests for comment.
Spain's move to restrict use of the shot caused widespread uncertainty and meant some younger people who had already received a first dose have been excluded from getting a second.
By extending the interval between doses, authorities will be able to evaluate the results of trials on mixing different vaccines before deciding whether those groups will receive a second AstraZeneca shot or another drug, the ministry said.
Spain's state-backed Carlos III Health Institute is investigating the effects of giving Pfizer (PFE.N) and BioNTech's (22UAy.DE) vaccine to patients who already received an AstraZeneca shot. read more
Spain's two-week coronavirus contagion rate fell slightly on Friday to 229 cases per 100,000 people compared with 230 on Thursday, according to health ministry data.
The cumulative number of cases rose to 3,524,077, while the total death rate was 78,216.
U.K’s Covid vaccine programme on track despite AstraZeneca problems
Three-quarters of population could be fully immunised by first week in August, according to forecasts
Apr 11, 2021
The UK’s vaccination programme is expected to be effectively completed shortly after the US’s this summer, and several weeks ahead of the EU’s effort, despite falling up to six weeks behind because of problems affecting the Oxford/AstraZeneca jab.
Airfinity, which tracks vaccination programmes worldwide, forecasts that 75% of the population can be fully immunised in the UK by the first week in August, a level where herd immunity arguably begins to take effect – though variants and the potential need for booster jabs could impact this significantly.
That would be about a week and a half behind the US, which can reach the same level by late July, but six weeks ahead of the EU, which the company estimates will achieve the same milestone towards the end of September.
“We expect the US to storm ahead. Production is going very well there and they are not exporting any doses,” said Matt Linley, a senior analyst with Airfinity. “The EU is also finally beginning to speed up too. But despite all the recent problems, the UK should still come out very well placed.”
Experts have repeatedly underlined the need for vaccine distribution to be global, including in developing countries, but there has been inevitable focus on frontrunners in the race so far. On Friday, Thierry Breton, the European commissioner leading Brussels’ vaccine taskforce, claimed that “like the fable of the tortoise and the hare”, the initially slow-moving EU vaccine campaign was accelerating as the UK rollout was beginning to flag.
The UK was the first country in the world to start vaccinating with the Pfizer/BioNTech jab last December, and with a seemingly healthy supply of AstraZeneca doses and an extraordinary mobilisation by the NHS, appeared well ahead of the EU, which failed to build up supply and distribution capacity quickly.
In the UK 31.8 million people, or at least 47.6% of the population, have had a first vaccine dose. But Britain’s decision to offer 10 million under-30s a jab other than AstraZeneca because of concerns about links to rare blood clots could delay the programme by up to four weeks, although Airfinity said the impact would depend on when new vaccines were approved and became available. Another fortnight was lost when India held back 5m doses of the same vaccine, the company estimates.
The Novavax jab, which is being produced and bottled in the UK, is expected to be approved in weeks and supplies are being prepared in advance. But in the past week, ministers said that the single-shot Johnson & Johnson jab, which will rapidly speed up any immunisation programme, would not be available until July, though it will reportedly be approved by the UK regulator within days. It is expected to be available in the EU, where it has already been approved, from 19 April.
An average of just over 3m doses a day are being administered in the US with the country benefiting from significant local supply of the Pfizer, Moderna and Johnson & Johnson vaccines. The AstraZeneca vaccine, which it has yet to authorise, may not be needed there.
Meanwhile, across the EU, intense efforts are being made to boost production and distribution as the 27-country bloc reels from a sluggish start worsened by production problems at AstraZeneca’s European plants.
In the past week, the EU ensured that almost all doses made for the company in the Netherlands would stay in the bloc, despite the UK having staked its claim to them. Britain had pressed unsuccessfully for a 50/50 split.
In Germany, GPs – who at the heart of the UK’s distribution success – were finally allowed to administer jabs this week, and in April daily doses per 100 people crept ahead of Britain for the first time since any vaccine became available, according to figures tracked by Our World in Data.
France, which began a lockdown amid rising cases at the end of March, has also closed the vaccination gap with the UK, although it is yet to forge ahead. This week, a plant in Normandy for bottling the Pfizer vaccine opened, and the country plans to have seven jab production facilities operating by the end of the year.
Martin McKee, a professor of European public health at the London School of Hygiene and Tropical Medicine, said: “The UK has benefited because it started earlier, and we are beginning to see other countries catching up. We also had an exceptional effort in the NHS, but you also have [the question of] how long is that sustainable for.”
https://amp.theguardian.com/society...ogramme-on-track-despite-astrazeneca-problems
@The_Renaissance You partying hard over there to celebrate the U.K's 35 Million inoculations milestone brah?
Haha, sadly I don't live near liverpool but my mate from there went and says it was great!
I've been doing a fair bit of socialising with mates in bars the past couple weeks though, outdoors only but the weathers been good for the most part!
Why did not a single person in that video have a mask on?
Got the Johnson and johnson shot yesterday. Fuck getting multiple shots.
@The_Renaissance You partying hard over there to celebrate the U.K's 35 Million inoculations milestone brah?